AI assistant
PCAS — Earnings Release 2013
Jul 23, 2013
1590_iss_2013-07-23_ca2b9a06-c85d-4076-9716-aa2ea6566351.pdf
Earnings Release
Open in viewerOpens in your device viewer
Longjumeau, July 23, 2013
| (in thousands of euros) | H1-2012 published (including SBS) |
H1-2012 restated (without SBS) |
H1-2013 | % change |
|---|---|---|---|---|
| Sales | 89 361 | 87 506 | 89 044 | + 1,8% |
| including Pharmaceutical | ||||
| Synthesis | 55 364 | 55 360 | 58 077 | + 4,9% |
| including Fine Speciality Chemicals | 33 997 | 32 146 | 30 967 | - 3,7 % |
(unaudited data)
For information, the sale of SBS was finalised on March 20, 2013. SBS was presented on a specific line as "Net Result on discontinued operation" as of December 31, 2012.
For the first half of 2013, the consolidated sales of the PCAS Group are up by 1.8% compared to the same period of the preceding year, without SBS.
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business has been continuing to develop in 2013 with growth of 4.9% relative to 2012.
Fine Specialty Chemicals
For the first half of 2013, Fine Specialty Chemicals are down (-3.7%) on 2012, affected by a sharp downturn in New Technologies business, while the Performance Chemicals business and, to a lesser extent, the Fragrance-Flavors-Cosmetics business have continued to grow.
The full six-monthly consolidated accounts will be examined by the Board of Directors on September 4, 2013.
About PCAS:
Founded in 1962, PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.